Jennifer Michaelson Sells 1,752 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) insider Jennifer Michaelson sold 1,752 shares of the firm’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $13.99, for a total value of $24,510.48. Following the sale, the insider directly owned 180,225 shares of the company’s stock, valued at $2,521,347.75. This represents a 0.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Jennifer Michaelson also recently made the following trade(s):

• On Wednesday, February 25th, Jennifer Michaelson sold 1,780 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $14.14, for a total value of $25,169.20.
• On Tuesday, February 24th, Jennifer Michaelson sold 3,601 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $14.47, for a total value of $52,106.47.
• On Friday, February 20th, Jennifer Michaelson sold 11,742 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $14.08, for a total value of $165,327.36.
• On Thursday, February 12th, Jennifer Michaelson sold 416 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $12.03, for a total value of $5,004.48.
• On Thursday, January 22nd, Jennifer Michaelson sold 4,000 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $12.30, for a total value of $49,200.00.
• On Friday, December 19th, Jennifer Michaelson sold 1,345 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $10.01, for a total transaction of $13,463.45.
• On Thursday, December 18th, Jennifer Michaelson sold 2,898 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $9.67, for a total transaction of $28,023.66.
• On Monday, December 15th, Jennifer Michaelson sold 995 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $11.90, for a total transaction of $11,840.50.
• On Friday, December 12th, Jennifer Michaelson sold 2,148 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $12.38, for a total transaction of $26,592.24.

Cullinan Therapeutics Price Performance

Shares of Cullinan Therapeutics stock opened at $15.21 on Friday. The company’s 50 day moving average price is $11.61 and its two-hundred day moving average price is $9.35. The firm has a market capitalization of $898.61 million, a P/E ratio of -4.60 and a beta of -0.09. Cullinan Therapeutics, Inc. has a fifty-two week low of $5.68 and a fifty-two week high of $15.23.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Guggenheim began coverage on shares of Cullinan Therapeutics in a research note on Monday, February 2nd. They issued a “buy” rating and a $30.00 price target for the company. Wedbush boosted their target price on Cullinan Therapeutics from $25.00 to $34.00 and gave the company an “outperform” rating in a research report on Tuesday, December 9th. HC Wainwright increased their price target on Cullinan Therapeutics from $26.00 to $27.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Zacks Research cut Cullinan Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 19th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $30.00 target price on shares of Cullinan Therapeutics in a research report on Thursday, January 8th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $29.33.

Institutional Investors Weigh In On Cullinan Therapeutics

Institutional investors have recently bought and sold shares of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Cullinan Therapeutics by 1.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 48,051 shares of the company’s stock worth $497,000 after purchasing an additional 888 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in Cullinan Therapeutics by 62.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,696 shares of the company’s stock worth $28,000 after buying an additional 1,036 shares during the period. Kennedy Capital Management LLC grew its stake in Cullinan Therapeutics by 2.7% in the 4th quarter. Kennedy Capital Management LLC now owns 47,266 shares of the company’s stock valued at $489,000 after buying an additional 1,255 shares in the last quarter. CWM LLC grew its stake in Cullinan Therapeutics by 51.5% in the 4th quarter. CWM LLC now owns 3,876 shares of the company’s stock valued at $40,000 after buying an additional 1,318 shares in the last quarter. Finally, Rafferty Asset Management LLC raised its holdings in Cullinan Therapeutics by 3.8% during the 3rd quarter. Rafferty Asset Management LLC now owns 40,729 shares of the company’s stock valued at $242,000 after acquiring an additional 1,503 shares during the period. Institutional investors own 86.31% of the company’s stock.

Cullinan Therapeutics News Roundup

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: Near-zero reported short interest reduces potential forced selling and can limit downside pressure, supporting the stock’s move higher. Short Interest Report
• Positive Sentiment: Analyst coverage is tilted positive: several firms (Guggenheim, Citi, HC Wainwright) carry Buy ratings and materially higher price targets than the current quote, creating an upside narrative that can attract buyers. Analyst Coverage
• Positive Sentiment: Institutional investors increased positions in Q4 (Invesco, Virtus, Susquehanna and others reported larger stakes), which can provide buying support and signal conviction from larger market participants. Institutional Activity
• Neutral Sentiment: Market context: broader risk-on/risk-off swings (crypto weakness noted in recent headlines) can affect small-cap biotechs indiscriminately; this is a macro factor rather than company-specific news. Macro/Crypto Headline
• Neutral Sentiment: Some shops have trimmed ratings recently (a few downgrades), creating dispersion in expectations—this can increase volatility but does not decisively change the bullish analyst narrative. Analyst Notes
• Negative Sentiment: Multiple senior insiders sold sizable blocks on Feb. 24–25, including CEO Nadim Ahmed (13,515 shares) and other executives—clustered insider sales can be perceived as insider monetization and pressure sentiment. CEO Sale Filing
• Negative Sentiment: Director/executive Jennifer Michaelson executed multiple recent sales (Feb. 23–25 series of transactions), further trimming insider holdings and amplifying concerns about insider cash-outs. Insider Trades Summary

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.